What is the recommended IV dose of Fosfomycin for a patient with a severe urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fosfomycin IV Dosing for Severe UTI

For severe urinary tract infections, intravenous fosfomycin should be dosed at 6 grams every 8 hours for 7 days, or 14 days if concurrent bacteremia is present. 1

Standard IV Dosing Regimen

  • 6 grams IV every 8 hours (total daily dose of 18 grams) is the evidence-based regimen for complicated upper urinary tract infections and severe UTIs 1, 2
  • Treatment duration is 7 days for complicated UTI without bacteremia 1
  • Extend to 14 days if concurrent bacteremia is documented 1

This dosing is derived from the ZEUS Phase 2/3 clinical trial, which demonstrated that IV fosfomycin was noninferior to piperacillin-tazobactam for complicated upper UTIs and actually superior for complicated lower UTIs, with excellent microbiological eradication rates against multidrug-resistant organisms including ESBL-producing E. coli and carbapenem-resistant Enterobacterales 1.

Alternative Dosing for Non-Critically Ill Patients

  • 4 grams IV every 6 hours is supported by pharmacokinetic/pharmacodynamic studies in non-critically ill patients with bacteremic UTI caused by multidrug-resistant E. coli 3
  • This regimen achieved adequate target attainment for 1-log bacterial burden reduction in 89-96% of patients when using EUCAST breakpoints 3
  • Higher doses (8g every 8 hours) showed only mild improvement over 4g every 6 hours but may increase toxicity without significantly improving efficacy 3

Key Clinical Considerations

When to Use IV Fosfomycin:

  • Severe complicated UTI or acute pyelonephritis requiring hospitalization 1, 2
  • Infections caused by multidrug-resistant Gram-negative organisms (ESBL, CRE, aminoglycoside-resistant) 1, 4
  • Patients who have failed first-line therapy 1
  • Documented susceptibility to fosfomycin in resistant organisms 4

Important Caveats:

  • Fosfomycin concentrations are highly variable between patients, partially explained by renal function 3
  • The drug is primarily renally excreted, requiring dose adjustment in renal impairment 4
  • Do not use for complicated intra-abdominal infections with septic shock - guidelines specifically exclude this scenario 4
  • Susceptibility testing is not routinely performed in many laboratories, so confirm availability of testing before relying on empiric coverage 4

Renal Dose Adjustments

While specific IV fosfomycin renal dosing is not well-established in the evidence provided, the drug requires monitoring in renal impairment given its renal excretion pathway 3. Baseline creatinine clearance determination is recommended 4.

Comparison to Oral Fosfomycin

Oral fosfomycin is NOT appropriate for severe UTI - it is only approved for uncomplicated cystitis 4, 1. The oral formulation (3g single dose) has lower bacterial eradication rates than other first-line agents and should be reserved for uncomplicated lower UTI 4.

References

Research

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020

Research

Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.